We are very pleased to announce that four faculty members were named 2024 Clarivate Highly Cited Researchers. Highly Cited Researchers have demonstrated significant and broad influence in their fields of research. Each researcher selected has authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade. However, citation activity is not the sole selection indicator. A preliminary list based on citation activity is then refined using qualitative analysis and expert judgment. Of the world’s population of scientists and social scientists, Highly Cited Researchers™ are 1 in 1,000.

Cornelius (Neil) Clancy, MD, Associate Chief of VA Pittsburgh Health System (VAPHS) and Opportunistic Pathogens, Professor of Medicine, Director of Mycology Program, and, Chief, Infectious Diseases Section VAPHS.

Significant publications include:

(1) Cheng S, Fleres G, Chen L, Liu G, Hao B, Newbrough A, Driscoll E, Shields RK, Squires KM, Chu TY, Kreiswirth BN, Nguyen MH, Clancy CJ. Within-Host Genotypic and Phenotypic Diversity of Contemporaneous Carbapenem-Resistant Klebsiella pneumoniae from Blood Cultures of Patients with Bacteremia. mBio. 2022 Dec 20;13(6):e0290622. Epub 2022 Nov 29. PMID: 36445082; PMCID: PMC9765435.

(2) Clancy CJ, Cornely OA, Marcella SW, Nguyen ST, Gozalo L, Cai B. Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study. Infect Drug Resist. 2024 Oct 15;17:4427-4443. PMID: 39431212; PMCID: PMC11490232

(3) Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.  Clin Infect Dis. 2023 Jul 18:ciad428. Epub ahead of print. PMID: 37463564.

Yohei Doi, MD, PhD, Professor of Medicine, and, Co-Director, Center for Innovative Antimicrobial Therapy.

Significant publications include:

(1) Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, Cober E, Alenazi T, Zong Z, Xie Q, Liu Z, Li L, Yu Y, Gao H, Kanj SS, Figueroa J, Herc E, Cordova E, Weston G, Ananth Tambyah P, Garcia-Diaz J, Kaye KS, Dhar S, Munita JM, Salata RA, Vilchez S, Stryjewski ME, Villegas Botero MV, Iovleva A, Evans SR, Baum K, Hill C, Kreiswirth BN, Patel R, Paterson DL, Arias CA, Bonomo RA, Chambers HF, Fowler VG Jr, Satlin MJ, van Duin D, Doi Y; Multi-Drug Resistant Organism Network Investigators. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clin Infect Dis. 2024 Feb 17;78(2):248-258. PMID: 37738153; PMCID: PMC10874260.

(2) McElheny CL, Iovleva A, Chen N, Woods D, Pradhan A, Sonnabend JL, Matunis AR, Raabe NJ, Lee JS, Trevejo-Nuñez G, Van Tyne D, Doi Y. Prevalence and features of hypervirulent Klebsiella pneumoniae in respiratory specimens at a US hospital system. Infect Immun. 2024 Dec 11:e0048624. Epub ahead of print. PMID: 39660916.

(3) Weston G, Giri A, Komarow L, Ge L, Baum KR, Abbenante E, Gallagher JC, Jacob JT, Kaye KS, Kim AC, Huskins WC, Zervos M, Herc E, Patel R, Van Duin D, Doi Y. Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales. J Antimicrob Chemother. 2024 Aug 1;79(8):1929-1937. PMID: 38863337; PMCID: PMC11290877.

(4) Kawai A, Shropshire WC, Suzuki M, Borjan J, Aitken SL, Bachman WC, McElheny CL, Bhatti MM, Shields RK, Shelburne SA, Doi Y. Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio. 2024 Feb 14;15(2):e0287423. Epub 2024 Jan 5. PMID: 38179965; PMCID: PMC10865806.

Minh-Hong Nguyen, MD, Professor of Medicine, Director of Transplant Infectious Diseases, and, Director of Antimicrobial Management Program.

Significant publications include:

(1) Badrane H, Cheng S, Dupont CL, Hao B, Driscoll E, Morder K, Liu G, Newbrough A, Fleres G, Kaul D, Espinoza JL, Clancy CJ, Nguyen MH. Genotypic diversity and unrecognized antifungal resistance among populations of Candida glabrata from positive blood cultures. Nat Commun. 2023 Sep 22;14(1):5918. PMID: 37739935; PMCID: PMC10516878.

(2) O’Donnell M, Eller AW, Waxman EL, Clancy CJ, Nguyen MH. Screening for Ocular Candidiasis Among Patients With Candidemia: Is It Time to Change Practice? Clin Infect Dis. 2022 Sep 29;75(6):1092-1096. PMID: 35325089.

(3) O’Donnell M, Shields RK, Marini RV, Groetzinger LM, Potoski BA, Falcione BA, Shah S, McCreary EK, Clarke L, Brant E, McVerry BJ, Liegey S, Pasculle AW, Clancy CJ, Nguyen MH. Stewardship-Guided T2Candida Testing Shortens Time to Antifungal Treatment and Reduces Antifungal Usage Among Medical Intensive Care Unit Patients With Septic Shock. Open Forum Infect Dis. 2023 Nov 8;10(11):ofad538. PMID: 38023565; PMCID: PMC10651185.

Ryan K. Shields, PharmD, MS, Associate Professor of Medicine, Co-Director, Center for Innovative Antimicrobial Therapy, and, Co-Director of Antimicrobial Management Program.

Significant publications include:

(1) Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifeuntes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Sarola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, Pogue JM. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2024 Dec 16:S1473-3099(24)00648-0. PMID: 39701120.

(2) Shields RK, Cheng WY, Kponee-Shovein K, Indacochea D, Gao C, Kuwer F, Joshi AV, Mitrani-Gold FS, Schwab P, Ferrinho D, Mahendran M, Pinheiro L, Royer J, Preib MT, Han J, Colgan R. Development of predictive models to inform a novel risk categorization framework for antibiotic resistance in E. coli causing uncomplicated urinary tract infection. Clin Infect Dis. 2024 Aug 16;79(2):295-304. PMID: 38573310; PMCID: PMC11327794.

(3) Shah S, Haidar G, Squires KM, Kline EG, Pogue JM, Ludwig J, McCreary EK, Stellfox M, Van Tyne D, Shields RK. Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia. Clin Infect Dis. 2024 Jun 21:ciae332. Epub ahead of print. PMID: 38902935.

(4) Shields RK, Dorazio AJ, Tiseo G, Squires KM, Giordano C, Kline EG, Barnini S, Iovleva A, Griffith MP, Van Tyne D, Doi Y, Falcone M. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC PMID: 39253335; PMCID: PMC11382143.

(5) Shah S, Clarke LG, Ludwig J, Burgdorf S, Arbulu RD, Shields RK. Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphyloccus aureus bacteremia and endocarditis. J Antimicrob Chemother. 2024 Aug 1;79(8):1990-1997. PMID: 38946294.

Please join us in congratulating Neil, Yohei, Hong and Ryan!